PLANT-DERIVED PHYTOCONSTITUENTS WITH ANTI-BREAST CANCER POTENTIAL: MECHANISTIC INSIGHTS, EVALUATION, AND THERAPEUTIC IMPLICATIONS
DOI:
https://doi.org/10.22159/ajpcr.2026v19i1.57323Keywords:
Breast cancer activity, Medicinal plants,, Phytoconstituents, Natural products.Abstract
This study reviews medicinal plants and their phytochemicals that show potential against breast cancer. Relevant research published up to August 2025 was collected from PubMed, Scopus, Web of Science, and Google Scholar. The selected studies reported anticancer activity, mechanisms, or IC50 values of plant-derived compounds in vitro and in vivo. These compounds were grouped as terpenoids, polyphenols, alkaloids, flavonoids, lignans, organosulfur compounds, and other bioactive molecules. Polyphenols (e.g., curcumin, resveratrol), terpenoids (e.g., withaferin A), and ginsenosides showed strong effects with low micromolar IC50 values, while alkaloids, such as vinblastine and vincristine demonstrated very high (nanomolar) potency. Some compounds, such as S-allyl cysteine and berberine, were less effective. Flavonoids, including epigallocatechin gallate and quercetin, showed notable anticancer activity. The main mechanisms involved are antioxidant action, immune modulation, hormone regulation, inhibition of metastasis and angiogenesis, and induction of cell cycle arrest and apoptosis. Overall, plant-based phytoconstituents show promising potential for breast cancer treatment and prevention, but issues, such as limited clinical evidence, poor bioavailability, and lack of standardization remain challenges. Advances in personalized medicine, synergistic therapies, standardized formulations, and nanotechnology may enhance their clinical use in the future.
Downloads
References
1. World Health Organization. Breast Cancer: Prevention and Control. Geneva: WHO; 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2023: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:129-52.
3. Rugo HS, Perez EA. Advances in the management of metastatic breast cancer: Targeted therapy and novel chemotherapeutic agents. Clin Cancer Res. 2021;27:3490-503.
4. Ninada KC, Bhagya N, Rodrigues WJ, Chandrashekar R, Chandrashekar KR. Anticancer potential of Salacia chinensis L. and Woodfordia fruticosa (L.) Kurz of the Western Ghats forests of India. Int J Pharm Pharm Sci. 2023;15(12):13-6.
5. Anil L, Mohandas S. In vitro antioxidant and anticancer activity of Macaranga peltata leaf extracts on lung cancer cell lines. Int J Curr Pharm Res. 2023;15(4):26-32.
6. Nair SS, Varkey J. Isolation of phytoconstituent, in vitro anticancer study in HeLa and MCF-7 cell lines and molecular docking studies of Pothos scandens Linn. Int J Curr Pharm Res. 2021;13(5):42-51. doi: 10.22159/ijcpr.2021v13i5.1882
7. Mudhafar M, Alsailawi HA, Abdulrasool MM, Jawad RK, Mays AD. Mini review of phytochemicals of ten Ficus species. Int J Chem Res. 2021;5(4):7-18. doi: 10.22159/ijcr.2021v5i4.185
8. Khan AQ, Rashid K, AlAmodi AA, Agha MV, Akhtar S, Hakeem I, et al. Role of flavonoids in breast cancer therapy: Focus on cellular signaling pathways and molecular targets. Cancers (Basel). 2020;12:498.
9. Efferth T, Oesch F. Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities. Semin Cancer Biol. 2020;80:39-57. doi: 10.1016/j.semcancer.2020.01.015, PMID 32027979
10. Yusuf M, Muhaimin M, Amalia R, Iskandar Y. Cytotoxic activity and phytochemical screening of ethanol extract of Bajakah tampala (Uncaria lanosa var. ferrea) stem on breast cancer cell lines MCF-7. Int J Appl Pharm. 2023;15 Suppl 2:44-7.
11. Bhutadiya VL, Mistry KN. A review on bioactive phytochemicals and it’s mechanism on cancer treatment and prevention by targeting multiple cellular signaling pathways. Int J Pharm Pharm Sci. 2021 Dec 1;13(12):15-9. doi: 10.22159/ijpps.2021v13i12.42798
12. Thakur M, Weng A, Fuchs H. Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Front Pharmacol. 2023;14:1152301.
13. Wali AF, Pillai JR, Talath S, Shivappa P, Sridhar SB, El-Tanani M, et al. Phytochemicals in breast cancer prevention and treatment: A comprehensive review. Curr Issues Mol Biol. 2025;47(1):30. doi: 10.3390/cimb47010030, PMID 39852145
14. Falzon L, Ritho C, Zarour H, Nair R. Systematic literature searching for evidence-based research: An overview of key resources. J Med Libr Assoc. 2023;111:252-63.
15. Nursoleha E, Utami W. Bibliometric analysis of drug resistance biomarkers in breast cancer (2020-2025). Int J App Pharm. 2025;17(4):10-8. doi: 10.22159/ijap.2025v17i4.54227
16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Updating guidance for reporting systematic reviews: Development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103-12. doi: 10.1016/j.jclinepi.2021.02.003, PMID 33577987
17. Kumari M, Vashisht K, Kumar M, Singh P, Kumar D, Balaraman AK, et al. An extensive analysis of the biochemical dimensions of phytochemicals in the treatment or prevention of breast cancer. Phytochem Rev. 2025 Apr 8;24(6):6223-53. doi: 10.1007/s11101-025- 10111-y
18. Wan ML, El-Nezami H, Pan Y, Wang MF, Cheng YK, Wong TL, et al. The role of phytochemicals in modulating the PI3K/Akt/mTOR pathway in breast cancer. Front Pharmacol. 2022;13:861328.
19. Cheriyan BV, Pandi K, Ramasamy J, Sooriyaprakash R, Jebaraj S. Phytochemicals, pathways, mechanisms and clinical applications: A comprehensive review on Hedyotis diffusa (Bai Hua She She Cao) in cancer management. Biomed Pharmacol J. 2025 May 20;18(2):1093-112. doi: 10.13005/bpj/3155
20. Khan H, Nabavi SM, Sureda A, Mehterov N, Gulei D, Berindan- Neagoe I, et al. Therapeutic potential of phytoconstituents in targeting breast cancer: Molecular insights and recent trends. Front Pharmacol. 2020;11:599087.
21. de Lima EP, Laurindo LF, Catharin VC, Direito R, Tanaka M, Jasmin Santos German I, et al. Polyphenols, alkaloids, and terpenoids against neurodegeneration: Evaluating the neuroprotective effects of phytocompounds through a comprehensive review of the current evidence. Metabolites. 2025 Feb 13;15(2):124.
22. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: An extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021 Jan 26;10(1):39. doi: 10.1186/s13643-020-01542-z, PMID 33499930
23. Ilango S, Sahoo DK, Paital B, Kathirvel K, Gabriel JI, Subramaniam K, et al. A review on Annona muricata and its anticancer activity. Cancers (Basel). 2022 Sep 19;14(18):4539. doi: 10.3390/cancers14184539, PMID 36139697
24. Mutakin M, Fauziati R, Fadhilah FN, Zuhrotun A, Amalia R, Hadisaputri YE. Pharmacological activities of soursop (Annona muricata Lin.). Molecules. 2022 Feb 10;27(4):1201. doi: 10.3390/ molecules27041201, PMID 35208993
25. Bravo-Alfaro DA, Montalvo-González E, Zapien-Macias JM, Sampieri-Moran JM, García HS, Luna-Bárcenas G. Annonaceae acetogenins: A potential treatment for gynecological and breast cancer. Fitoterapia. 2024 Oct 1;178:106187. doi: 10.1016/j.fitote.2024.106187, PMID 39147170
26. Malhotra M, Rana H, Tandon S. Exploring the therapeutic potential of Catharanthus roseus: Unveiling its diverse phytochemicals and mechanisms of action for chronic and infectious diseases. Int J Curr Pharm Res. 2024;16(5):1-8. doi: 10.22159/ijcpr.2024v16i5.5023
27. Banyal A, Tiwari S, Sharma A, Chanana I, Patel SK, Kulshrestha S, et al. Vinca alkaloids as a potential cancer therapeutics: recent update and future challenges. 3 Biotech. 2023 Jun;13(6):211. doi: 10.1007/ s13205-023-03636-6, PMID 37251731
28. Dhyani P, Quispe C, Sharma E, Bahukhandi A, Sati P, Attri DC, et al. Anticancer potential of alkaloids: A key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. Cancer Cell Int. 2022 Jun 2;22(1):206. doi: 10.1186/s12935-022-02624-9, PMID 35655306
29. Thompson KN, Ju JA, Ory EC, Pratt SJ, Lee RM, Mathias TJ, et al. Microtubule disruption reduces metastasis more effectively than primary tumor growth. Breast Cancer Res. 2022 Feb 14;24(1):13. doi: 10.1186/s13058-022-01506-2, PMID 35164808
30. Olofinsan K, Abrahamse H, George BP. Therapeutic role of alkaloids and alkaloid derivatives in cancer management. Molecules. 2023 Jul 22;28(14):5578. doi: 10.3390/molecules28145578, PMID 37513450
31. Zhong XD, Chen LJ, Xu XY, Liu YJ, Tao F, Zhu MH, et al. Berberine as a potential agent for breast cancer therapy. Front Oncol. 2022 Sep 2;12:993775. doi: 10.3389/fonc.2022.993775, PMID 36119505
32. Xiong RG, Huang SY, Wu SX, Zhou DD, Yang ZJ, Saimaiti A, et al. Anticancer effects and mechanisms of berberine from medicinal herbs: An update review. Molecules. 2022 Jul 15;27(14):4523. doi: 10.3390/ molecules27144523, PMID 35889396
33. Li Q, Zhao H, Chen W, Huang P. Berberine induces apoptosis and arrests the cell cycle in multiple cancer cell lines. Arch Med Sci. 2021 Mar 21;19(5):1530-7. doi: 10.5114/aoms/132969, PMID 37732040
34. Qian K, Tang CY, Chen LY, Zheng S, Zhao Y, Ma LS, et al. Berberine reverses breast cancer multidrug resistance based on fluorescence pharmacokinetics in vitro and in vivo. ACS Omega. 2021 Apr 13;6(16):10645-54. doi: 10.1021/acsomega.0c06288, PMID 34056218
35. Sood A, Mehrotra A, Sharma U, Aggarwal D, Singh T, Shahwan M, et al. Advancements and recent explorations of anti-cancer activity of chrysin: From molecular targets to therapeutic perspective. Explor Target Antitumor Ther. 2024 May 23;5(3):477-94. doi: 10.37349/ etat.2024.00230, PMID 38966181
36. Raina R, Bhatt R, Hussain A. Chrysin targets aberrant molecular signatures and pathways in carcinogenesis. World Acad Sci J. 2024 Jun 26;6(5):45.
37. Ma J, Liu P, Pan L. Network pharmacology unveils the intricate molecular landscape of chrysin in breast cancer therapeutics. Discov Oncol. 2025 Feb 23;16(1):228. doi: 10.1007/s12672-025-01951-3, PMID 39987541
38. Sevinc SK, Çıkla-Süzgün P, Tiber PM, Güniz Küçükgüzel Ş, Orun O. Biological activities of etodolac-based hydrazone, thiazolidinone and triazole derivatives on breast cancer cell lines MCF‐7 and MDA‐MB‐231. J Biochem Mol Toxicol. 2025 Aug;39(8):e70428. doi: 10.1002/jbt.70428, PMID 40787711
39. Yennawar R, Abjani N, Parekh N, Budha RR, Kaur G, Joshi H, et al. Genistein and gastrointestinal cancers: A comprehensive review of recent studies and future outlook. J Biochem Mol Toxicol. 2025 Oct;39(10):e70533. doi: 10.1002/jbt.70533, PMID 41026609
40. Zuo Y, Zhang CZ, Ren Q, Chen Y, Li X, Yang JR, et al. Activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway by voacamine suppress breast cancer progression. Phytomedicine. 2022 May 1;99:154015. doi: 10.1016/j.phymed.2022.154015, PMID 35278901
41. Yusuf H, Satria D, Suryawati S, Fahriani M. Combination therapy of eurycomanone and doxorubicin as anticancer on T47D and MCF-7 Cell Lines. Syst Rev Pharm. 2020 Oct 1;11(10):335-41.
42. Aghemo A, Alekseeva OP, Angelico F, Bakulin IG, Bakulina NV, Bordin D, et al. Role of silymarin as antioxidant in clinical management of chronic liver diseases: A narrative review. Ann Med. 2022 Dec 31;54(1):1548-60. doi: 10.1080/07853890.2022.2069854, PMID 35635048
43. Tat SS, Mandal K, Sharma T, Ghate NB, Barik GK, Gachhe RN, et al. The multifaceted role of PUMA in cell death pathways: Its therapeutic potential across cancer types. Cell Commun Signal. 2025 Nov 20;23(1):499. doi: 10.1186/s12964-025-02112-3, PMID 41267117
44. Koushki M, Khedri A, Aberomand M, Akbari Baghbani KA, Mohammadzadeh G. Synergistic anti-cancer effects of silibinin-etoposide combination against human breast carcinoma MCF-7 and MDA-MB-231 cell lines. Iran J Basic Med Sci. 2021 Sep;24(9):1211-9. doi: 10.22038/ijbms.2021.56341.12575, PMID 35083008
45. Bernasinska-Slomczewska J, Hikisz P, Pieniazek A, Koceva-Chyla A. Baicalin and baicalein enhance cytotoxicity, proapoptotic activity, and genotoxicity of doxorubicin and docetaxel in MCF-7 breast cancer cells. Molecules. 2024 May 25;29(11):2503. doi: 10.3390/ molecules29112503, PMID 38893380
46. Fossatelli L, Maroccia Z, Fiorentini C, Bonucci M. Resources for human health from the plant kingdom: The potential role of the flavonoid apigenin in cancer counteraction. Int J Mol Sci. 2023 Dec 23;25(1):251. doi: 10.3390/ijms25010251, PMID 38203418
47. Ma Y, Pan Y, Zhao Q, Zhang C, He H, Pan L, et al. Exploring the therapeutic potential and in vitro validation of baicalin for the treatment of triple-negative breast cancer. Front Pharmacol. 2025 Apr 28;16:1530056. doi: 10.3389/fphar.2025.1530056, PMID 40356970
48. Susmitha GD, Miyazato K, Ogura K, Yokoyama S, Hayakawa Y. Anti-metastatic effects of baicalein by targeting STAT3 activity in breast cancer cells. Biol Pharm Bull. 2020 Dec 1;43(12):1899-905. doi: 10.1248/bpb.b20-00571, PMID 33268707
49. Liu H, Dong Y, Gao Y, Du Z, Wang Y, Cheng P, et al. The effects of baicalein on metastasis of breast cancer: A systematic review and meta-analysis of preclinical studies. Phytomedicine. 2020;68:153179.
50. Adel M, Zahmatkeshan M, Akbarzadeh A, Rabiee N, Ahmadi S, Keyhanvar P, et al. Chemotherapeutic effects of apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles. Biotechnol Rep (Amst). 2022 Jun 1;34:e00730. doi: 10.1016/j.btre.2022.e00730, PMID 35686000
51. Pandita G, Mittal D, Kashyap P, Lai WF, Kumar N, Mehra R, et al. Apigenin and its derivatives in breast cancer prevention and therapy: A review on bioavailability and recent developments. Phytomed Plus. 2025 Aug 14;5(4):100870. doi: 10.1016/j.phyplu.2025.100870
52. Parveen S, Bhat IU, Bhat R. Kaempferol and its derivatives: Biological activities and therapeutic potential. Asian Pac J Trop Biomed. 2023 Oct 1;13(10):411-20. doi: 10.4103/2221-1691.387747
53. Amjad E, Sokouti B, Asnaashari S. A systematic review of anti-cancer roles and mechanisms of kaempferol as a natural compound. Cancer Cell Int. 2022 Aug 20;22(1):260. doi: 10.1186/s12935-022-02673-0, PMID 35986346
54. de Morais EF, de Oliveira LQ, Farias Morais HG, Souto Medeiros MR, Freitas RA, Rodini CO, et al. The anticancer potential of kaempferol: A systematic review based on in vitro studies. Cancers (Basel). 2024 Jan 30;16(3):585. doi: 10.3390/cancers16030585, PMID 38339336
55. Raksha B, Vaishnavi M, Durga M, Brindha BB, Deepikaa R. Nanoencapsulation of luteolin: Enhancing bioavailability and medicinal benefits. Int J Pharm Pharm Sci. 2023;49440. doi: 10.22159/ ijpps. 2023v15i12
56. Rocchetti MT, Bellanti F, Zadorozhna M, Fiocco D, Mangieri D. Multi-faceted role of luteolin in cancer metastasis: EMT, angiogenesis, ECM degradation and apoptosis. Int J Mol Sci. 2023 May 16;24(10):8824. doi: 10.3390/ijms24108824, PMID 37240168
57. Rakoczy K, Kaczor J, Sołtyk A, Szymańska N, Stecko J, Sleziak J, et al. Application of luteolin in neoplasms and nonneoplastic diseases. Int J Mol Sci. 2023 Nov 6;24(21):15995. doi: 10.3390/ijms242115995, PMID 37958980
58. Maugeri A, Calderaro A, Patanè GT, Navarra M, Barreca D, Cirmi S, et al. Targets involved in the anti-cancer activity of quercetin in breast, colorectal and liver neoplasms. Int J Mol Sci. 2023 Feb 2;24(3):2952. doi: 10.3390/ijms24032952, PMID 36769274
59. Asgharian P, Tazekand AP, Hosseini K, Forouhandeh H, Ghasemnejad T, Ranjbar M, et al. Potential mechanisms of quercetin in cancer prevention: Focus on cellular and molecular targets. Cancer Cell Int. 2022 Aug 15;22(1):257. doi: 10.1186/s12935-022-02677-w, PMID 35971151
60. Sakao K, Hamamoto S, Urakawa D, He Z, Hou DX. Anticancer activity and molecular mechanisms of acetylated and methylated quercetin in human breast cancer cells. Molecules. 2024 May 20;29(10):2408. doi: 10.3390/molecules29102408, PMID 3879226961. Wu ZY, Qiu KY, Gai YJ, Wu JH, Zhou BX, Shi QF. Quercetin: A natural ally in combating breast cancer. Int J Nanomedicine. 2025 Dec 31;20:9155-77. doi: 10.2147/IJN.S518174, PMID 40708864
62. Stepień AE, Trojniak J, Tabarkiewicz J. Anti-oxidant and anti-cancer properties of flaxseed. Int J Mol Sci. 2025 Jan 30;26(3):1226. doi: 10.3390/ijms26031226, PMID 39940995
63. Al-Madhagy S, Ashmawy NS, Mamdouh A, Eldahshan OA, Farag MA. A comprehensive review of the health benefits of flaxseed oil in relation to its chemical composition and comparison with other omega-3-rich oils. Eur J Med Res. 2023 Jul 18;28(1):240. doi: 10.1186/s40001-023-01203-6, PMID 37464425
64. Fabian CJ, Khan SA, Garber JE, Dooley WC, Yee LD, Klemp JR, et al. Randomized phase IIB trial of the lignan secoisolariciresinol diglucoside in premenopausal women at increased risk for development of breast cancer. Cancer Prev Res (Phila). 2020 Jul 1;13(7):623-34. doi: 10.1158/1940-6207.CAPR-20-0050, PMID 32312713
65. Chaudhary A, Patil P, Raina P, Kaul-Ghanekar R. Matairesinol repolarizes M2 macrophages to M1 phenotype to induce apoptosis in triple-negative breast cancer cells. Immunopharmacol Immunotoxicol. 2025 Jan 2;47(1):8-22. doi: 10.1080/08923973.2024.2425028, PMID 39722605
66. Mahajan A, Sharma N, Ulhe A, Patil R, Hegde M, Mali A. From dietary lignans to cancer therapy: Integrative systems analysis of enterolactone’s molecular targets and signaling pathways in combatting cancer stem cells in triple-negative breast cancer. Food Biosci. 2024 Apr 1;58:103732. doi: 10.1016/j.fbio.2024.103732
67. Lee W, Song G, Bae H. Matairesinol induces mitochondrial dysfunction and exerts synergistic anticancer effects with 5-fluorouracil in pancreatic cancer cells. Mar Drugs. 2022 Jul 25;20(8):473. doi: 10.3390/md20080473, PMID 35892941
68. Burgberger M, Mierziak J, Augustyniak B, Wojtasik W, Kulma A. The power of lignans: Plant compounds with multifaceted health-promoting effects. Metabolites. 2025 Sep 4;15(9):589. doi: 10.3390/ metabo15090589, PMID 41002973
69. Tanwar AK, Dhiman N, Kumar A, Jaitak V. Engagement of phytoestrogens in breast cancer suppression: Structural classification and mechanistic approach. Eur J Med Chem. 2021 Mar 5;213:113037. doi: 10.1016/j.ejmech.2020.113037, PMID 33257172
70. Soltani M, Fotovat R, Sharifi M, Ahmadian Chashmi NA, Behmanesh M. In vitro comparative study on antineoplastic effects of pinoresinol and lariciresinol on healthy cells and breast cancer-derived human cells. Iran J Med Sci. 2024 Jan 1;49(1):30-9. doi: 10.30476/ ijms.2023.94805.2611, PMID 38322161
71. Dar NJ, Gull B, Hamid A, Ahmed Z, Ahmad M. Withaferin-A kills neuronal cells: An off-putting facet of Withania somnifera as a neuroprotectant. Steroids. 2025 Jul 20;222:109662. doi: 10.1016/j. steroids.2025.109662, PMID 40695418
72. Chen X, Ma X, Hu X, Wang C, Zhang X, Yan C. Mechanisms and potential therapeutic strategies of withaferin A in breast cancer. Pharmacol Rep. 2025 May 20;77(5):1163-76. doi: 10.1007/s43440- 025-00736-3, PMID 40392517
73. Mishra SD, Mendonca P, Kaur S, Soliman KF. Silibinin anticancer effects through the modulation of the tumor immune microenvironment in triple-negative breast cancer. Int J Mol Sci. 2025 Jun 28;26(13):6265. doi: 10.3390/ijms26136265, PMID 40650040
74. Rajendran P, Renu K, Abdallah BM, Ali EM, Veeraraghavan VP, Sivalingam K, et al. Nimbolide: Promising agent for prevention and treatment of chronic diseases (recent update). Food Nutr Res. 2024 Mar 18;68. doi: 10.29219/fnr.v68.9650, PMID 38571915
75. Nivetha R, Arvindh S, Baba AB, Gade DR, Gopal G, Chitrathara K, et al. Nimbolide, a neem limonoid, inhibits angiogenesis in breast cancer by abrogating aldose reductase mediated IGF-1/PI3K/Akt signalling. Anti-cancer agents in medicinal chemistry-anti-cancer agents. 2022 Aug 1;22(14):2619-36.
76. Arumugam A, Subramani R, Lakshmanaswamy R. Involvement of actin cytoskeletal modifications in the inhibition of triple-negative breast cancer growth and metastasis by nimbolide. Mol Ther Oncolytics. 2021 Mar 26;20:596-606. doi: 10.1016/j. omto.2021.02.014, PMID 33768141
77. Gharge S, Hiremath SI, Kagawad P, Jivaje K, Palled MS, Suryawanshi SS. Curcuma zedoaria Rosc (Zingiberaceae): A review on its chemical, pharmacological and biological activities. Future J Pharm Sci. 2021 Aug 23;7(1):166. doi: 10.1186/s43094-021-00316-1
78. Zhao P, Qiu J, Pan C, Tang Y, Chen M, Song H, et al. Potential roles and molecular mechanisms of bioactive ingredients in Curcumae rhizoma against breast cancer. Phytomedicine. 2023 Jun 1;114:154810. doi: 10.1016/j.phymed.2023.154810, PMID 37075623
79. Cui T, Li BY, Liu F, Xiong L. Research progress on sesquiterpenoids of Curcumae rhizoma and their pharmacological effects. Biomolecules. 2024 Mar 23;14(4):387. doi: 10.3390/biom14040387, PMID 38672405
80. Sati P, Sharma E, Dhyani P, Attri DC, Rana R, Kiyekbayeva L, et al. Paclitaxel and its semi-synthetic derivatives: Comprehensive insights into chemical structure, mechanisms of action, and anticancer properties. Eur J Med Res. 2024 Jan 30;29(1):90. doi: 10.1186/s40001- 024-01657-2, PMID 38291541
81. Szwed M, Michlewska S, Kania K, Szczęch M, Marczak A, Szczepanowicz K. New SDS-based polyelectrolyte multicore nanocarriers for paclitaxel delivery-synthesis, characterization, and activity against breast cancer cells. Cells. 2023 Aug 11;12(16):2052. doi: 10.3390/cells12162052, PMID 37626862
82. Sharifi-Rad J, Quispe C, Patra JK, Singh YD, Panda MK, Das G, et al. Paclitaxel: Application in modern oncology and nanomedicine-based cancer therapy. Oxid Med Cell Longev. 2021;2021(1):3687700. doi: 10.1155/2021/3687700, PMID 34707776
83. Yang Q, Zhai X, Lv Y. A bibliometric analysis of triptolide and the recent advances in treating non-small cell lung cancer. Front Pharmacol. 2022 May 30;13:878726. doi: 10.3389/fphar.2022.878726, PMID 35721205
84. Feng K, Li X, Bai Y, Zhang D, Tian L. Mechanisms of cancer cell death induction by triptolide: A comprehensive overview. Heliyon. 2024 Jan 30;10(2):e24335. doi: 10.1016/j.heliyon.2024.e24335, PMID 38293343
85. Hong OY, Jang HY, Park KH, Jeong YJ, Kim JS, Chae HS. Triptolide inhibits matrix metalloproteinase-9 expression and invasion of breast cancer cells through the inhibition of NF-κB and AP-1 signaling pathways. Oncol Lett. 2021 Jul;22(1):562. doi: 10.3892/ ol.2021.12823, PMID 34093777
86. Prompoon Y, Yurasakpong L, Suwannakhan A, Chawiwithaya C, Chotwiwatthanakun C, Weerachatyanukul W, et al. Betulinic acid inhibits proliferation and triggers apoptosis in human breast cancer cells by modulating ER (α/β) and p53. Scienceasia. 2024 Oct 1;50(5):1. doi: 10.2306/scienceasia1513-1874.2024.085
87. Chen P, Zhang X, Fang Q, Zhao Z, Lin C, Zhou Y, et al. Betulinic acid induces apoptosis of HeLa cells via ROS-dependent ER stress and autophagy in vitro and in vivo. J Nat Med. 2024 Jun;78(3):677-92. doi: 10.1007/s11418-024-01782-6, PMID 38403724
88. Li X, Li D. Natural compounds targeting cellular redox homeostasis in malignancies. Cell Mol Biol (Noisy-le-grand). 2023 Dec 20;69(14):255-65. doi: 10.14715/cmb/2023.69.14.43, PMID 38279422
89. Khwaza V, Oyedeji OO, Aderibigbe BA. Ursolic acid-based derivatives as potential anti-cancer agents: An update. Int J Mol Sci. 2020 Aug 18;21(16):5920. doi: 10.3390/ijms21165920, PMID 32824664
90. Michalak O, Cybulski M, Szymanowski W, Gornowicz A, Kubiszewski M, Ostrowska K, et al. Synthesis, biological activity, ADME and molecular docking studies of novel ursolic acid derivatives as potent anticancer agents. Int J Mol Sci. 2023 May 17;24(10):8875. doi: 10.3390/ijms24108875, PMID 37240221
91. Yang K, Xie Z, Liu S, Xu R, Mao J, Feng W, et al. Ursolic acid affects autophagy and apoptosis of breast cancer through PLK1 via AKT/mTOR signaling pathway. Med Oncol. 2025 Jul 21;42(8):358. doi: 10.1007/s12032-025-02917-9, PMID 40691672
92. Shaban S, Chahkandi T, Jafari-Nozad AM, Farkhondeh T, Samarghandian S. A review on the potential effects of curcumin in the treatment of neuroblastoma and its underlying mechanisms. Curr Med Chem. 2025 Dec;32(42):9570-87. doi: 10.2174/010929867334569324 1218070409, PMID 39835551
93. El-Saadony MT, Saad AM, Mohammed DM, Alkafaas SS, Ghosh S, Negm SH, et al. Curcumin, an active component of turmeric: Biological activities, nutritional aspects, immunological, bioavailability, and human health benefits-a comprehensive review. Front Immunol. 2025 Aug 21;16:1603018. doi: 10.3389/fimmu.2025.1603018, PMID 40918117
94. Nunes YC, Mendes NM, Pereira de Lima E, Chehadi AC, Lamas CB, Haber JF, et al. Curcumin: A golden approach to healthy aging: A systematic review of the evidence. Nutrients. 2024 Aug 15;16(16):2721. doi: 10.3390/nu16162721, PMID 39203857
95. Barcelos KA, Mendonça CR, Noll M, Botelho AF, Francischini CR, Silva MA. Antitumor properties of curcumin in breast cancer based on preclinical studies: A systematic review. Cancers(Basel). 2022 Apr 26;14(9):2165. doi: 10.3390/cancers14092165, PMID 35565294
96. Marín V, Burgos V, Pérez R, Maria DA, Pardi P, Paz C. The potential role of epigallocatechin-3-gallate (EGCG) in breast cancer treatment. Int J Mol Sci. 2023 Jun 27;24(13):10737. doi: 10.3390/ijms241310737, PMID 37445915
97. Kubatka P, Bojkova B, Nosalova N, Huniadi M, Samuel SM, Sreenesh B, et al. Targeting the MAPK signaling pathway: Implications and prospects of flavonoids in 3P medicine as modulators of cancer cell plasticity and therapeutic resistance in breast cancer patients. EPMA J. 2025 Jun;16(2):437-63. doi: 10.1007/s13167-025-00407-6, PMID 40438489
98. Steed KL, Jordan HR, Tollefsbol TO. SAHA and EGCG promote apoptosis in triple-negative breast cancer cells, possibly through the modulation of cIAP2. Anticancer Res. 2020 Jan 1;40(1):9-26. doi: 10.21873/anticanres.13922, PMID 31892549
99. Şabik AE, Sevindik M, Mohammed FS, Uysal I, Bal C. Gallic acid: Derivatives and biosynthesis, pharmacological and therapeutic effect, biological activity. BUASVMCN-FST. 2024;81(1):18-27. doi: 10.15835/buasvmcn-fst:2023.0017
100. Mamat N, Mahyun NN, Muhamad N, Hapidin H, Abdullah H. Gallic acid in combination with cisplatin triggered apoptosis in mcf-7 breast cancer cells. Malays J Microsc. 2025 Jun 1;21(1):183-93.
101. Saini U, Sharma A, Mittal V. Gallic acid: A potent antioxidant and anti-inflammatory agent in modern cosmeceuticals. Recent Adv Drug Deliv Formul. 2025 May 26;20:345-58. doi: 10.2174/0126673878341 990250516063126, PMID 40442901
102. Shruthi S, Mumbrekar KD, Rao BS, Shenoy BK. Gallic acid: A polyphenolic compound potentiates the therapeutic efficacy of cisplatin in human breast cancer cells. Toxicol Res (Camb). 2023 Aug;12(4):544-50. doi: 10.1093/toxres/tfad041, PMID 37663803
103. Moga MA, Dimienescu OG, Bălan A, Dima L, Toma SI, Bîgiu NF, et al. Pharmacological and therapeutic properties of Punica granatum phytochemicals: Possible roles in breast cancer. Molecules. 2021 Feb 17;26(4):1054. doi: 10.3390/molecules26041054, PMID 33671442
104. Evtyugin DD, Magina S, Evtuguin DV. Recent advances in the production and applications of ellagic acid and its derivatives. A review. Molecules. 2020 Jun 13;25(12):2745. doi: 10.3390/ molecules25122745, PMID 32545813
105. Djaldetti M. Ellagic acid-a dietary polyphenol with anticancer activity that deserves more consideration. Recent Prog Nutr. 2023 Jul;3(3):1-32. doi: 10.21926/rpn.2303011
106. Unnikrishnan J, Hegde M, Girisa S, Satpati P, Kunnumakkara AB. Ellagic acid-gold nanoparticle complex as anticancer agent in Triple-negative breast cancer cells. Nano Life. 2024 Jun 6;14(2):2450003. doi: 10.1142/S179398442450003X
107. Behroozaghdam M, Dehghani M, Zabolian A, Kamali D, Javanshir S, Hasani Sadi F, et al. Resveratrol in breast cancer treatment: From cellular effects to molecular mechanisms of action. Cell Mol Life Sci. 2022 Nov;79(11):539. doi: 10.1007/s00018-022-04551-4, PMID 36194371
108. Hamad S, Musleh Z, Nasir K, Hameed A, Eskander G. Resveratrol inhibits Cell cycle dynamics, caspase activation, and programmed cell death: Implications for cancer treatment in MCF-7 cells. Egypt J Vet Sci. 2024 Nov 1;55(6):1659-68. doi: 10.21608/ejvs.2024.263893.1787
109. Rais N, Ved A, Ahmad R, Kumar M, Deepak Barbhai MD, Radha D, et al. S-allyl-L-cysteine-a garlic bioactive: Physicochemical nature, mechanism, pharmacokinetics, and health promoting activities. J Funct Foods. 2023 Aug 1;107:105657. doi: 10.1016/j.jff.2023.105657
110. Dong R, Wang J, Guan R, Sun J, Jin P, Shen J. Role of oxidative stress in the occurrence, development, and treatment of breast cancer. Antioxidants (Basel). 2025 Jan 17;14(1):104. doi: 10.3390/ antiox14010104, PMID 39857438
111. Cho HM, Ryu YC, Park J, Hwang BH. Synergistic therapeutic efficacy of Selective Anticancer Complex in triple-negative breast cancer. Biomed Pharmacother. 2025 Apr 1;185:117983. doi: 10.1016/j. biopha.2025.117983, PMID 40090282
112. Bronowicka-Adamska P, Bentke A, Lasota M, Wróbel M. Effect of S-allyl-l-cysteine on MCF-7 cell line 3-mercaptopyruvate sulfurtransferase/sulfane sulfur system, viability and apoptosis. Int J Mol Sci. 2020 Feb 6;21(3):1090. doi: 10.3390/ijms21031090, PMID 32041330
113. Bentke-Imiolek A, Szlęzak D, Zarzycka M, Wróbel M, Bronowicka- Adamska P. S-allyl-L-cysteine affects cell proliferation and expression of H2S-synthetizing enzymes in MCF-7 and MDA-MB-231 adenocarcinoma cell lines. Biomolecules. 2024 Feb 4;14(2):188. doi: 10.3390/biom14020188, PMID 38397425
114. Song X, Yue Z, Nie L, Zhao P, Zhu K, Wang Q. Biological functions of diallyl disulfide, a garlic-derived natural organic sulfur compound. Evid Based Complement Alternat Med. 2021;2021(1):5103626. doi: 10.1155/2021/5103626, PMID 34745287
115. Mathan SV, Singh R, Kim SH, Singh SV, Singh RP. Diallyl trisulfide induces ROS-mediated mitotic arrest and apoptosis and inhibits HNSCC tumor growth and cancer stemness. Cancers (Basel). 2024 Jan 16;16(2):378. doi: 10.3390/cancers16020378, PMID 38254868
116. Zhou YF, Zhu YW, Wang YW, Liang XY, Jiang QY, Wu DD. Diallyl disulfide in oncotherapy: Molecular mechanisms and therapeutic potentials. Apoptosis. 2025 May 15;30(7-8):1730-50. doi: 10.1007/ s10495-025-02105-0, PMID 40375038
117. Gunasekaran K, Thangavelu P, Thangavelu P, Kalagatur NK, Jeyaraj R, Samiappan S. Unveiling the effects of cisplatin and diallyl disulfide on MDA-MB-231 breast cancer cells. Curr Trends Biotechnol Pharm. 2024 Jul 31;18(3):1813-21. doi: 10.5530/ctbp.2024.3.29
118. Malla R, Marni R, Chakraborty A, Kamal MA. Diallyl disulfide and diallyl trisulfide in garlic as novel therapeutic agents to overcome drug resistance in breast cancer. J Pharm Anal. 2022 Apr 1;12(2):221-31. doi: 10.1016/j.jpha.2021.11.004, PMID 35582397
119. Lu L, Gao Z, Song J, Jin L, Liang Z. The potential of diallyl trisulfide for cancer prevention and treatment, with mechanism insights. Front Cell Dev Biol. 2024 Sep 30;12:1450836. doi: 10.3389/fcell.2024.1450836, PMID 39403128
120. Chang CM, Wang WJ, Mhone TG, Ho WK, Chen CJ, Ng SS, et al. Diallyl trisulfide enhances doxorubicin chemosensitivity by inhibiting the Warburg effect and inducing apoptosis in breast cancer cells. J Cancer. 2025 Jul 11;16(11):3283-95. doi: 10.7150/jca.113578, PMID 40861817
121. Coutinho LL, Junior TC, Rangel MC. Sulforaphane: An emergent anti-cancer stem cell agent. Front Oncol. 2023 Jan 23;13:1089115. doi: 10.3389/fonc.2023.1089115, PMID 36776295.
122. Liu P, Zhang B, Li Y, Yuan Q. Potential mechanisms of cancer prevention and treatment by sulforaphane, a natural small molecule compound of plant-derived. Mol Med. 2024 Jun 21;30(1):94. doi: 10.1186/s10020-024-00842-7, PMID 38902597
123. Sailo BL, Liu L, Chauhan S, Girisa S, Hegde M, Liang L, et al. Harnessing sulforaphane potential as a chemosensitizing agent: A comprehensive review. Cancers (Basel). 2024 Jan 5;16(2):244. doi: 10.3390/cancers16020244, PMID 38254735
124. Al-Damook N, Sakkal M, Khair M, Mousa WK, Khoder G, Ghemrawi R. Targeting cancer through thymoquinone: From molecular mechanisms to clinical prospects. Int J Mol Sci. 2025 Nov 14;26(22):11029. doi: 10.3390/ijms262211029, PMID 41303508
125. Shabani H, Karami MH, Kolour J, Sayyahi Z, Parvin MA, Soghala S, et al. Anticancer activity of thymoquinone against breast cancer cells: Mechanisms of action and delivery approaches. Biomed Pharmacother. 2023 Sep 1;165:114972. doi: 10.1016/j.biopha.2023.114972, PMID 37481931
126. Adinew GM, Taka E, Mochona B, Badisa RB, Mazzio EA, Elhag R, et al. Therapeutic potential of thymoquinone in triple-negative breast cancer prevention and progression through the modulation of the tumor microenvironment. Nutrients. 2021 Dec 25;14(1):79. doi: 10.3390/nu14010079, PMID 35010954
127. Yang Y, Nan Y, Du Y, Liu W, Ning N, Chen G, et al. Ginsenosides in cancer: Proliferation, metastasis, and drug resistance. Biomed Pharmacother. 2024 Aug 1;177:117049. doi: 10.1016/j. biopha.2024.117049, PMID 38945081
128. Nakhjavani M, Smith E, Yeo K, Palethorpe HM, Tomita Y, Price TJ, et al. Anti-angiogenic properties of ginsenoside Rg3 epimers: In vitro assessment of single and combination treatments. Cancers (Basel). 2021 May 6;13(9):2223. doi: 10.3390/cancers13092223, PMID 34066403
129. Tanko AI, Hosawi S, Moglad E, Afzal M, Ghaboura N, Alzareaa SI, et al. Ginsenoside Rg3 in cancer research: Current trends and future prospects-A review. Curr Med Chem. 2025 Jan 14;32(31):6740-63. doi: 10.2174/0109298673333781240924024342
130. Hasan MR, Alotaibi BS, Althafar ZM, Mujamammi AH, Jameela J. An update on the therapeutic anticancer potential of Ocimum sanctum L.: “Elixir of life”. Molecules. 2023 Jan 25;28(3):1193. doi: 10.3390/ molecules28031193, PMID 36770859
131. Padhy I, Paul P, Sharma T, Banerjee S, Mondal A. Molecular mechanisms of action of eugenol in cancer: Recent trends and advancement. Life (Basel). 2022 Nov 6;12(11):1795. doi: 10.3390/ life12111795, PMID 36362950
132. Noman AM, Sultan MT, Mazhar A, Khan WA, Imran M, Hussain M, et al. Eugenol: An insight into the anticancer perspective and pharmacological aspects. Food Sci Nutr. 2025 Aug;13(8):e70727. doi: 10.1002/fsn3.70727, PMID 40761498
133. Mustafa M, Ahmad R, Tantry IQ, Ahmad W, Siddiqui S, Alam M, et al. Apoptosis: A comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications. Cells. 2024 Nov 6;13(22):1838. doi: 10.3390/ cells13221838, PMID 39594587
134. Shukla S, Shukla AK, Upadhyay AM, Ray N, Fahad FI, Nagappan A, et al. Molecular insight and antioxidative therapeutic potentials of plant-derived compounds in breast cancer treatment. Onco. 2025 Jun 9;5(2):27. doi: 10.3390/onco5020027
135. Machado H, Machado J, Alves C, Monteiro MC, Cruz A, Pinho C, et al. A narrative review on breast cancer treatment supported by focused and systemic phytotherapy. Nutraceuticals. 2025 Nov 10;5(4):37. doi: 10.3390/nutraceuticals5040037
136. Batool S, Asim L, Qureshi FR, Masood A, Mushtaq M, Saleem RS. Molecular targets of plant-based alkaloids and Polyphenolics in liver and breast cancer- an insight into anticancer drug development. Anticancer Agents Med Chem. 2025 Mar;25(5):295-312. doi: 10.2174 /0118715206302216240628072554, PMID 38963106
137. Haque M, Shyanti RK, Mishra MK. Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer. Front Oncol. 2024 Oct 10;14:1431418. doi: 10.3389/fonc.2024.1431418, PMID 39450256
138. Sohel M. Breaking barriers; phytoestrogens in the fight against triple-negative breast cancer: A comprehensive review. Med Res Rev. 2025 Jul;45(4):1211-50. doi: 10.1002/med.22107, PMID 40072262
139. Singh S. Review on natural agents as aromatase inhibitors: Management of breast cancer. Comb Chem High Throughput Screen. 2024 Nov;27(18):2623-38. doi: 10.2174/01138620732695992310091 15338, PMID 37861041
140. Bishayee A, Ahmed S, Brankov N, Khwairakpam AD, Das J. Phytochemicals as multi-targeted anti-cancer agents: Recent advances in breast cancer therapy. Phytomedicine. 2022;101:154136.
141. Bishayee A, Khwairakpam AD, Darvesh AS. Phytochemicals as anticancer agents: Progress, challenges, and future directions. Semin Cancer Biol. 2021;69:34-50.
142. Sun S, Yu Y, Jo Y, Han JH, Xue Y, Cho M, et al. Impact of extraction techniques on phytochemical composition and bioactivity of natural product mixtures. Front Pharmacol. 2025 Jul 30;16:1615338. doi: 10.3389/fphar.2025.1615338, PMID 40808686
143. Aljabali AA, Obeid MA, Bashatwah RM, Qnais E, Gammoh O, Alqudah A, et al. Phytochemicals in cancer therapy: A structured review of mechanisms, challenges, and progress in personalized treatment. Chem Biodivers. 2025 Aug;22(8):e202402479. doi: 10.1002/cbdv.202402479, PMID 40192260
144. Chen YS, Jin E, Day PJ. Use of drug sensitisers to improve therapeutic index in cancer. Pharmaceutics. 2024 Jul 11;16(7):928. doi: 10.3390/ pharmaceutics16070928, PMID 39065625
145. Vieira IR, Conte-Junior CA. Nano-delivery systems for food bioactive compounds in cancer: Prevention, therapy, and clinical applications. Crit Rev Food Sci Nutr. 2024 Jan 13;64(2):381-406. doi: 10.1080/10408398.2022.2106471, PMID 35938315
146. Hernández-Lorca M, Timón IM, Ballester P, Henarejos-Escudero P, García-Muñoz AM, Victoria-Montesinos D, et al. Dietary modulation of CYP3A4 and its impact on statins and antidiabetic drugs: A narrative review. Pharmaceuticals (Basel). 2025 Sep 9;18(9):1351. doi: 10.3390/ ph18091351, PMID 41011221
147. Li M, Fang G, Zahid F, Saleem R, Ishrat G, Ali Z, et al. Co-delivery of paclitaxel and curcumin loaded solid lipid nanoparticles for improved targeting of lung cancer: In vitro and in vivo investigation. Heliyon. 2024 May 15;10(9):e30290. doi: 10.1016/j.heliyon.2024.e30290, PMID 38720725
148. Cetiner K, Seko I, Uluturk S, Gur B, Sahin A, Capan Y. Development and in vitro evaluation of quercetin loaded folic acid conjugated PLGA nanoparticles for the treatment of breast cancer. Lat Am J Pharm. 2024;43(10):2177-83.
149. Wang Z, Fu S, Han Y, Wang J, Cao J, Wang J, et al. Ternary composite nanoparticles to improve the water solubility and stability of resveratrol: Preparation, characterization and bioavailability. Food Chem. 2025 May 15;474:143258. doi: 10.1016/j.foodchem.2025.143258, PMID 39938304
150. Bhattacharya S, Mukherjee B, Ray S. Nanotechnology-based approaches for enhancing the therapeutic potential of plant-derived anticancer compounds. Int J Nanomedicine. 2020;15:6671-91.
151. Shao Q, Feng Y, Wang W, Wang M, Li B, El Tahchi M, et al. Drug carrier for sustained release of withaferin A for pancreatic cancer treatment. J Mater Sci. 2020 Feb;55(4):1702-14. doi: 10.1007/s10853- 019-04139-7
152. Parvin N, Aslam M, Joo SW, Mandal TK. Nano-phytomedicine: Harnessing plant-derived phytochemicals in nanocarriers for targeted human health applications. Molecules. 2025 Jul 29;30(15):3177. doi: 10.3390/molecules30153177, PMID 40807355
153. Devan AR, Nair B, Nath LR. Translational phytomedicines against cancer: Promise and hurdles. Adv Pharm Bull. 2022 Apr 28;13(2):210-5. doi: 10.34172/apb.2023.023, PMID 37342376
154. Kaur K, Sharma V, Kabila B, Sidhu MC. The science of omics: A recent approach for screening and enhancement of bioactive compounds in medicinal plants. In: Biotechnological Innovations for Sustainable Biodiversity and Development. United States: CRC Press; 2025. p. 59-67.
155. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770- 803. doi: 10.1021/acs.jnatprod.9b01285, PMID 32162523
Published
How to Cite
Issue
Section
Copyright (c) 2025 velmurugan.v, Pranavi juturu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.